Balaxi Pharmaceuticals Reports Robust Q2 FY27 With PAT Surging 450% YoY
Balaxi Pharmaceuticals Ltd · Investor Presentation · 16 Nov 2026, 6:06 pm
Balaxi Pharmaceuticals Reports Robust Q2 FY27 With PAT Surging 450% YoY Balaxi Pharmaceuticals delivered strong consolidated Q2 FY27 results, with revenue from operations rising 44.85% YoY to ₹8,137.23 lakh and total income growing 39.44% YoY to ₹8,054.38 lakh. EBITDA increased 55.88% YoY to ₹429.23 lakh, expanding margins by 56 bps to 5.33%. PAT surged 450.33% YoY to ₹115.02 lakh with diluted EPS of ₹0.21. For H1 FY27, revenue reached ₹16,205.40 lakh (+27.68% YoY) and PAT stood at ₹244.76 lakh (+390.40% YoY). Growth was driven by operationalization of the Jadcherla OSD facility and expanding market reach across LATAM and Africa.
Original exchange filing (PDF)
More announcements from Balaxi Pharmaceuticals Ltd
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding a press release dated November 12, 2026, titled "Balaxi Pharmaceuticals Limited Reports Strong Q2 FY27 Performance; Revenue Grows 45%, EBITDA Surges 338% and PAT Rises 450% YoY". · 13 Nov 2026
- Balaxi Pharmaceuticals Limited has informed the Exchange regarding Progress of the Company's Pharmaceutical Formulation Plant at Jadcherla, Hyderabad. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about change in Management · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding Outcome of Board Meeting held on November 12, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has submitted to the Exchange, the financial results for the period ended September 30, 2026. · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange regarding ''RTA Report for Re-lodgement of Transfer Requests of Physical Shares for the period ended October 2026". · 12 Nov 2026
- BALAXI PHARMACEUTICALS LIMITED has informed the Exchange about Board Meeting to be held on 12-Nov-2026 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2026 and Other business. · 12 Nov 2026
- To consider and approve the Unaudited Standalone and Consolidated financial results of the Company for the second quarter and half year ended 30th September, 2026 of the Financial Year 2026-27, and other business matters. · 12 Nov 2026
